Castle Biosciences, Inc.
Castle Biosciences, Inc.
Your view on CSTL
Overview
What the company does, where it operates, and who runs it.
About Castle Biosciences, Inc.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Derek J. Maetzold
- Headquarters
- 505 South Friendswood Drive, Friendswood, TX, US
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Derek J. Maetzold
- Headquarters
- 505 South Friendswood Drive, Friendswood, TX, US
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.
The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions.
It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Castle Biosciences, Inc., and the rating behind it. CSTL last traded at $32.33; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Castle Biosciences, Inc.. Starting points for Castle Biosciences, Inc.: EPS -$0.64, beta 0.99 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Castle Biosciences, Inc.. Castle Biosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Castle Biosciences, Inc.. Trailing twelve-month EPS for Castle Biosciences, Inc. stands at -$0.64. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Castle Biosciences, Inc.. Castle Biosciences, Inc. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Castle Biosciences, Inc. valued side by side against its closest peers. Castle Biosciences, Inc. is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Castle Biosciences, Inc., and how their positions are changing. At a $987.7M market value, institutional positions materially move Castle Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Castle Biosciences, Inc. executives and directors. Shares of Castle Biosciences, Inc. have traded between $14.59 and $35.49 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Castle Biosciences, Inc.. Castle Biosciences, Inc. is a $987.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Castle Biosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Castle Biosciences, Inc.. Coverage tracks Castle Biosciences, Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.